Department of Nephrology, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK.
Arch Dis Child. 2011 Sep;96(9):881-2. doi: 10.1136/archdischild-2011-300172. Epub 2011 Jun 19.
Two recent trials of angiotensin II receptor blockers (ARBs) were performed in children 0-5 years of age. Data from the published reports of these trials together with additional information from the sponsoring drug companies were obtained. Three deaths occurred in the 183 (1.6%) hypertensive children participating in the two trials. At least two of these deaths occurred in children known to be susceptible to drugs acting on the renin-angiotensin system, that is, children with ongoing nephrotic syndrome and acute gastroenteritis. Clinicians who prescribe ARBs in preschool children need to be aware of the risk of drug toxicity especially in children susceptible to intravascular dehydration. Clinicians should consider discontinuing the drugs in the presence of acute diarrhoea.
两项最近的血管紧张素 II 受体阻滞剂（ARB）试验在 0-5 岁儿童中进行。从已发表的这些试验报告中的数据，以及来自赞助药物公司的其他信息中获取。在参与这两项试验的 183 名（1.6%）高血压儿童中，有 3 例死亡。其中至少有两例死亡发生在已知易受影响肾素-血管紧张素系统药物作用的儿童中，即患有持续性肾病综合征和急性肠胃炎的儿童。在学龄前儿童中开处方 ARB 的临床医生需要意识到药物毒性的风险，尤其是在易发生血管内脱水的儿童中。在出现急性腹泻时，临床医生应考虑停止使用这些药物。
